Nektar Therapeutics has agreed to sell its manufacturing facility in Huntsville, Alabama, to Ampersand Capital Partners for $90 million, consisting of $70 million in cash and $20 million in equity, with the deal expected to close in Q4 2024.
AI Assistant
NEKTAR THERAPEUTICS
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.